408 related articles for article (PubMed ID: 25966433)
1. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Schweitzer N; Vogel A
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
[TBL] [Abstract][Full Text] [Related]
2. Cholangiocellular Carcinoma.
Vogel A; Saborowski A
Digestion; 2017; 95(3):181-185. PubMed ID: 28288474
[TBL] [Abstract][Full Text] [Related]
3. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
Jensen LH; Jakobsen A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
[TBL] [Abstract][Full Text] [Related]
4. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
Valle JW; Furuse J; Jitlal M; Beare S; Mizuno N; Wasan H; Bridgewater J; Okusaka T
Ann Oncol; 2014 Feb; 25(2):391-8. PubMed ID: 24351397
[TBL] [Abstract][Full Text] [Related]
6. [Systemic treatment of biliary tract cancer].
Jensen LH; Larsen O
Ugeskr Laeger; 2013 Oct; 175(42):2478-81. PubMed ID: 24629114
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Guion-Dusserre JF; Lorgis V; Vincent J; Bengrine L; Ghiringhelli F
World J Gastroenterol; 2015 Feb; 21(7):2096-101. PubMed ID: 25717243
[TBL] [Abstract][Full Text] [Related]
8. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Marciano R; Servetto A; Bianco C; Bianco R
J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
[TBL] [Abstract][Full Text] [Related]
9. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy.
Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Arihiro K; Takahashi S
Clin J Gastroenterol; 2022 Dec; 15(6):1164-1168. PubMed ID: 36181621
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
Merath K; Tiwari A; Parikh AA; Pawlik TM
Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
Ricci AD; D'Alessandro R; Rizzo A; Schirizzi A; Vallarelli S; Ostuni C; Troiani L; Lolli IR; Lotesoriere C; Giannelli G
Immunotherapy; 2023 May; 15(7):477-486. PubMed ID: 36950960
[TBL] [Abstract][Full Text] [Related]
14. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
15. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in cholangiocarcinoma.
Beri N
Immunotherapy; 2023 May; 15(7):541-551. PubMed ID: 37096964
[TBL] [Abstract][Full Text] [Related]
17. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs.
Spolverato G; Glavas D; Hewitt DB; Brown ZJ; Capelli G; Bergamo F; Rizzato MD; Pawlik TM
Expert Opin Pharmacother; 2022 Mar; 23(4):473-481. PubMed ID: 34964678
[TBL] [Abstract][Full Text] [Related]
18. [A case of curative resection after downsizing chemotherapy in initially unresectable locally advanced intrahepatic cholangiocarcinoma].
Aoki Y; Suzuki T; Kato A; Shimizu H; Ohtsuka M; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takano S; Okamura D; Suzuki D; Sakai N; Kagawa S; Miyazaki M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1509-11. PubMed ID: 25731235
[TBL] [Abstract][Full Text] [Related]
19. Exploring Molecular Mechanisms in the Second-Line Treatment of Biliary Tract Malignant Tumors.
Liu Q; Zhang P; Li Q
Discov Med; 2024 Jan; 36(180):48-60. PubMed ID: 38273745
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of ivosidenib for the treatment of
Tella SH; Mahipal A
Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
